A long holding period can make exchange-traded fund (ETF) investing much simpler.

Rather than trying to guess which market will perform best over the next few months, investors can focus on funds with broad exposure, durable themes, and the ability to compound over many years.

Here are three ASX ETFs that could be worth buying and holding for a decade or more.

iShares S&P 500 ETF (ASX: IVV)

The first ASX ETF to look at is the iShares S&P 500 ETF.

This fund gives investors exposure to 500 of the largest listed companies in the United States. That makes it a simple way to access many of the world’s most influential businesses through a single ASX trade.

The appeal is not just the size of the market. The S&P 500 includes companies across technology, healthcare, financials, consumer goods, and industrials. This gives the fund exposure to a wide range of earnings drivers.

Its holdings include names such as Microsoft (NASDAQ: MSFT), Amazon (NASDAQ: AMZN), and Berkshire Hathaway (NYSE: BRK.B).

For long-term investors, this fund offers a straightforward way to participate in the growth of corporate America without needing to pick individual winners.

iShares Global Consumer Staples ETF (ASX: IXI)

Another ASX ETF that could suit a long holding period is the iShares Global Consumer Staples ETF.

Consumer staples companies sell products that people tend to buy regardless of economic conditions. This includes food, beverages, household goods, personal care products, and other everyday essentials.

That gives this fund a more defensive profile than many growth-focused ETFs.

Its underlying companies may not always be the fastest growers, but they can offer steady earnings and pricing power through different market environments.

Its holdings include companies such as Costco Wholesale (NASDAQ: COST), Walmart (NASDAQ: WMT), and Nestle (SWX: NESN).

This type of exposure can be useful over a decade or more because it is tied to recurring consumer demand. People continue to buy groceries, cleaning products, and household essentials in strong and weak economies alike.

Vanguard MSCI Index International Shares ETF (ASX: VGS)

A third ASX ETF worth considering is the Vanguard MSCI Index International Shares ETF.

This fund provides broad exposure to developed share markets outside Australia. This includes companies listed in the United States, Europe, Japan, and other major economies.

The fund is designed to give investors access to global growth in a simple way. Rather than relying heavily on the Australian market, it spreads exposure across thousands of international companies.

Its holdings include Apple (NASDAQ: AAPL), NVIDIA (NASDAQ: NVDA), and JPMorgan Chase (NYSE: JPM).

This breadth is the main attraction. The Vanguard MSCI Index International Shares ETF gives investors exposure to different industries, currencies, and economic regions, helping reduce reliance on any single market.

For those looking to build global exposure through the ASX, it arguably remains one of the most straightforward options to hold for the long term.

The post 3 strong ASX ETFs to buy and hold for a decade or more appeared first on The Motley Fool Australia.

More reading

• How to become a millionaire with ASX shares starting with $0
• Why I’d buy these ASX ETFs if I had $500 spare
• Here’s why I think ASX growth investors should embrace index investing in 2026
• Inside the Vanguard MSCI Index International Shares ETF (VGS)’s big April gain
• How to shave a decade off retirement with 3 ASX stocks and ETFs

JPMorgan Chase is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Amazon, Apple, Berkshire Hathaway, Costco Wholesale, JPMorgan Chase, Microsoft, Nvidia, Walmart, and iShares S&P 500 ETF. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Nestlé. The Motley Fool Australia has recommended Amazon, Apple, Berkshire Hathaway, Microsoft, Nvidia, Vanguard Msci Index International Shares ETF, and iShares S&P 500 ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) enjoyed another strong day this Thursday, building on the stunning session we saw yesterday. By the time trading wrapped up, the ASX 200 had gained a solid 0.96%, leaving the index at 8,878.1 points.

This impressive showing from the local markets comes after a similarly jubilant night over on the American boards.

The Dow Jones Industrial Average Index (DJX: .DJI) was on fire last night, shooting 1.2% higher.

The tech-heavy Nasdaq Composite Index (NASDAQ: .IXIC) was even hotter, rising 2.02%.

But let’s return ot the ASX now and check out how today’s optimism filtered down into the different ASX sectors this session.

Winners and losers

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

More reading

• Neuren Pharmaceuticals Q1 2026: DAYBUE sales soar
• Cleanaway Waste Management hit with landfill levy ruling
• Why Megaport shares are rocketing 40% in a month
• Why is this ASX industrial stock storming higher today?
• How ASX 200 gold stocks like Newmont, Evolution Mining and Northern Star shares have their shine back today

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Megaport and Temple & Webster Group. The Motley Fool Australia has recommended Temple & Webster Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you have $20,000 available to invest in May, the ASX growth shares in this article could be worth a closer look.

Let’s see why they could be standout picks this month:

WiseTech Global Ltd (ASX: WTC)

The first ASX growth share that continues to stand out is WiseTech Global.

WiseTech provides software to the global logistics industry through its CargoWise platform. This software helps freight forwarders, customs brokers, and logistics providers manage complex cross-border supply chains.

It operates in a large, fragmented industry that is still becoming more digital, and global logistics is full of manual processes, regulatory complexity, and time-sensitive decisions. That creates a strong need for software that can improve efficiency and reduce friction.

WiseTech has also expanded its product suite through acquisitions and internal development, giving it more ways to deepen relationships with customers.

As logistics companies continue investing in technology, WiseTech appears well placed to capture more of that spending.

Hub24 Ltd (ASX: HUB)

Another ASX growth share worth looking at in May is investment platform provider Hub24.

It has been benefiting from a long-running shift away from legacy wealth platforms toward newer, more flexible technology.

Funds under administration are a key driver for the business. As more advisers move client assets onto the platform, Hub24 can grow revenue while also benefiting from scale.

The company has built a strong position in a competitive market by focusing on functionality, service, and adviser needs. That has helped it win market share from larger incumbents. In fact, it continues to report market share gains quarter after quarter. This saw it recently reveal a market share of 9.7%, which was up from 8.3% a year ago.

With Australia’s wealth management industry still evolving, Hub24 has a long runway if it can keep attracting advisers and growing platform balances.

Life360 Inc (ASX: 360)

A third ASX growth share to look at is Life360.

It has built a global platform focused on family safety, location sharing, and digital protection. Its app is used by around 100 million people, giving the company a large base from which to grow.

The opportunity is increasingly about turning engagement into earnings. Life360 can do this by converting more users into paying subscribers and expanding the services available within its platform.

This makes the business more interesting than a simple app story. It is building a subscription ecosystem around safety, mobility, and family connectivity. It has even launched a pet service too.

If Life360 continues improving monetisation while growing its global user base, it could deliver strong earnings growth over the coming years.

The post 3 amazing ASX growth shares to buy in May with $20,000 appeared first on The Motley Fool Australia.

More reading

• Generation Development Group completes $1.8bn client migration
• Why Life360 shares are a strong buy this week
• 5 things to watch on the ASX 200 on Thursday
• 3 of the best Aussie ASX growth shares to buy and hold until 2036
• 3 ASX 200 shares on my May watchlist

Motley Fool contributor James Mickleboro has positions in Life360 and WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Hub24, Life360, and WiseTech Global. The Motley Fool Australia has positions in and has recommended Life360 and WiseTech Global. The Motley Fool Australia has recommended Hub24. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are up 0.8% to 8,865.9 points on Thursday.

The market has rallied on hopes of a US-Iran peace deal.

Meanwhile, Morgans has updated its ratings and price targets on three ASX shares.

Let’s check them out.

Minerals 260 Ltd (ASX: MI6)

The Minerals 260 share price is 75 cents, down 1.7% today but up 474% over 12 months.

In a new note, Morgans said the gold miner had awarded a building contract for a 400-person accommodation village at Bullabulling.

The broker said this marks “a key step toward development” for the ASX mineral explorer.

Ongoing drilling continues to support resource growth, conversion and strike continuity, reinforcing confidence in the scale and quality of the system.

As a result, our confidence in Bullabulling’s commerciality strengthens and update our model to reflect a larger-scale operation …

We maintain our BUY rating and lift our price target to A$1.40ps (from A$1.20ps), driven by the increased scale and improved production profile under our revised development scenario.

Atlas Arteria Ltd (ASX: ALX)

The Atlas Arteria share price is $4.79, down 0.6% today but up 13% over the past month.

The recent gain is due to a hostile takeover bid from IFM Investors.

Atlas Arteria’s independent directors have recommended that shareholders reject the offer of $4.75 per share.

Morgans moved from a trim to a hold rating this week. It has a share price target of $4.22 on the toll roads operator.

The broker said:

ALX recommended its investors ignore IFM’s hostile off-market takeover bid, citing the offer price as too low, the timing opportunistic, and the offer highly conditional. It also disclosed it initiated a sale process for its interest in Chicago Skyway which, if successful, could be value accretive (at least to our valuation).

While the Chicago Skyway divestment process is underway we moderate our rating from TRIM to HOLD given potential for value realisation above what we consider to be the intrinsic value of the asset and hence driving our ALX valuation up close to where the share price is currently trading.

Super Retail Group Ltd (ASX: SUL)

The Super Retail share price is $11.20, down 4% today and down 16.4% over 12 months.

Morgans released a note today maintaining its hold rating on this ASX retail share. Its price target is $12.90.

The broker said:

SUL delivered a softer trading update, with all divisions seeing a deceleration in LFL sales through Mar/Apr (group LFL -2%) and group gross margin compression.

Weaker consumer sentiment from inflationary pressures (fuel and rates) weighed over the key Easter period as the promotional environment remains intense.

Limited earnings visibility and a challenging backdrop persist, with capital management initiatives unlikely to feature in FY26.

The post Buy, hold, or sell? Minerals 260, Atlas Arteria, Super Retail shares appeared first on The Motley Fool Australia.

More reading

• Why Light & Wonder, Super Retail, Tabcorp, and Woodside shares are falling today
• Why are Super Retail shares crashing 13% today?
• 5 things to watch on the ASX 200 on Thursday
• Super Retail Group provides a trading update
• Which ASX 200 stock is lifting after a hostile takeover update?

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Super Retail Group. The Motley Fool Australia has positions in and has recommended Super Retail Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Most ASX lithium stocks are rising on Thursday amid a 58% increase in the lithium carbonate price in 2026 alone.

The lithium carbonate price is US$27,528 per tonne at the time of writing.

It rose nearly 6% in the last trading session and is up 18% over the past month and 181% year over year.

Lithium carbonate is now at its highest level since 2023 amid renewed and growing long-term demand for lithium batteries.

The lithium spodumene price has also ripped from less than US$600 per tonne in June last year to US$2,752 per tonne today.

Lithium prices endured a two-year downward spiral before turning a corner in mid-2025 as supply and demand rebalanced.

The green energy transition is the key driver of new demand, while the global oil shock has highlighted the draw of electric vehicles (EVs).

On top of that, supply has rebalanced after many young lithium miners shuttered their operations in 2023 and 2024 as prices collapsed.

Analysts at Trading Economics said:

The surge in crude oil and product prices since the start of March supported the outlook for larger economies to favor new energy vehicles, which use batteries that take lithium as a major input.

Demand also remained supported by Chinese investment in power infrastructure, recently consolidated with Beijing stating it would double national EV charging capacity to 180 gigawatts by 2027.

Fresh buying is also featured from data center operators, whose power storage systems require more lithium than those used by EVs, on the historical capital investments by AI companies and hardware producers.

Lithium is leaving other commodities in the dust when it comes to year-to-date (YTD) growth.

The 58% gain for lithium carbonate compares to 3.5% for iron ore, 8.9% for gold, 8% for copper, and 9% for silver.

How are ASX lithium stocks performing today?

Today, the best performing ASX lithium shares for price growth include IGO Ltd (ASX: IGO), up 4.3% to $8.43 per share.

The IGO share price is up 2.6% in the YTD and 103% over 12 months.

Mineral Resources Ltd (ASX: MIN) shares are up 2.1% to $71.42 on Thursday.

The Mineral Resources share price is up 29% in the YTD and up 242% over 12 months.

The Liontown Ltd (ASX: LTR) share price is down 1.2% today at $2.51.

However, Liontown shares have been on a tear this year, up 55% YTD and up 348% over 12 months.

The market’s largest pure-play lithium company, PLS Group Ltd (ASX: PLS), cracked a new record at $6.38 today.

The PLS Group share price is currently $6.34, up 1.6% for the day and up 47.1% in the YTD.

Which ASX lithium stocks are a buy?

On the CommSec trading platform, IGO shares have a consensus moderate buy rating from 16 analysts.

UBS is among the brokers with a buy recommendation.

Late last month, the broker raised its price target from $9.05 to $9.75, implying a 15% upside from here.

Mineral Resources has a consensus moderate buy rating among 15 analysts tracking the ASX lithium stock on CommSec.

Morgans has an accumulate rating and recently raised its 12-month target from $67 to $71.

In a new note, the broker described a “compelling outlook supported by continued deleveraging and commodity prices”.

Liontown shares have a consensus hold rating among 12 analysts rating it on CommSec.

Morgans downgraded Liontown shares from hold to trim but with an improved $2.20 price target this week.

The broker said:

Weak 3Q26 result was driven by lower recoveries, though ramp-up is progressing well and cash flow turned positive.

Outlook is improving with recoveries and spodumene prices lifting.

Move to a TRIM with a A$2.20ps TP on valuation but the outlook remains positive.

PLS Group shares score a consensus moderate hold rating from 18 analysts on CommSec.

The hold rating is unsurprising given the market’s largest ASX lithium stock by market cap is trading at record price levels.

Bell Potter is among the brokers with a hold rating on PLS Group shares.

In a recent note, the broker said:

At current lithium market prices, PLS will generate substantial earnings and cash flow ahead of the restart of the 200ktpa Ngungaju processing plant.

P2000 and Colina development studies are being progressed, providing substantial organic growth optionality in markets with strong underlying EV and BESS-led long term demand fundamentals.

The post ASX lithium stocks to buy amid commodity price rocketing 58% already this year appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Mineral Resources, Fortescue, Champion Iron shares
• 4 top ASX 200 shares including Rio Tinto and Macquarie notching new 52-week plus highs today
• Up more than 100% in a year, is it time to take profits on IGO shares?
• Here are the top 10 ASX 200 shares today
• Buy, hold, sell: Mineral Resources, Dyno Nobel, Iluka Resources shares

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

4DMedical Ltd (ASX: 4DX) shares are being sold off again on Thursday as investors take another look at one of the ASX’s hottest stocks.

At the time of writing, the 4DMedical share price is down a sizeable 10.39% to $3.405.

That puts the stock down around 40% over the past month. It also leaves the share price more than 50% below its recent high of $7.37, which was reached on 14 April.

While the move is not being driven by any new announcements today, the sell-off appears tied to weaker momentum after a huge recent run.

Here’s what investors are looking at.

A huge rally is now unwinding

This pullback follows a massive run in the share price.

Even after the recent drop, 4DMedical shares are still up around 1,040% since this time last year.

The stock has been helped by a string of updates over the past 12 months. These include regulatory progress, commercial agreements, and stronger interest in the company’s lung imaging technology.

Its CT:VQ platform uses existing CT scans to create detailed maps of lung ventilation and blood flow. 4DMedical has previously highlighted US clearance, UK certification, and a commercial contract with GlaxoSmithKline as key steps.

That run helped send the share price to an all-time high in April.

Since then, investors appear to have been locking in gains as sentiment has cooled.

The stock has recorded several heavy down days, falling 5.47% yesterday and more than 20% over the past week.

The chart looks under pressure

The technical picture has also weakened.

The stock has broken well below its recent highs and is now trading near the bottom end of its recent range. The overall trend since mid-April has been lower, with each bounce struggling to hold.

The relative strength index (RSI) is sitting around 29, which puts the stock close to oversold territory. Meanwhile, the Bollinger Bands show the share price trading near the lower end of its recent range.

The lower band is sitting around $2.75, while the upper band is above $5.

From here, the first support area looks to be around $3.30, near the recent intraday low. If that breaks, the next level to watch could be closer to the lower Bollinger Band near $2.75.

Foolish takeaway

I can see why investors are taking some money off the table after such a big run.

4DMedical has clear commercial progress, but the stock had raced a long way ahead of current earnings.

Personally, I would not be chasing this sell-off today. I would want to see the share price settle first, especially around the $3.30 support area.

The post Why this ASX 200 rocket stock is crashing again today appeared first on The Motley Fool Australia.

More reading

• Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?
• Buy, hold, sell: Minerals 260, 4DMedical, Karoon Energy shares
• Why this ASX healthcare high-flyer just dropped another 9% today
• The ASX’s hottest shares just stumbled — warning sign?
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Are you looking for ASX dividend shares to buy? If you are, it could be worth considering the two in this article.

That’s because Morgans has just rated them as buys and is forecasting attractive dividend yields. Here’s what the broker is recommending to clients:

Accent Group Ltd (ASX: AX1)

The first ASX dividend share that could be a buy according to Morgans is footwear retailer Accent Group.

While it has been a tough period for the company, Morgans thinks its shares have been oversold, creating an opportunity for investors.

It has put a buy rating and 75 cents price target on its shares. It said:

AX1 has provided a soft trading update for 2H26, revising guidance lower and disclosed an ASIC insider trading investigation. The trading update for AX1 has materially softened since the update in February, with the escalations in the Middle East resulting in higher fuel prices and lower consumer confidence which in turn has impacted sales and margins. 2H26 EBIT guidance has been lowered to $23-28m (from $30-35m). We have lowered our EBIT by 9%/6% respectively in FY26/27.

Our valuation lowers to $1.00, which we apply a 25% discount to derive a target price of $0.75. This reflects the weakening consumer backdrop, as well as overhang from ASIC investigation. We maintain our BUY recommendation.

With respect to income, the broker is forecasting fully franked dividends per share of 3.8 cents in FY 2026 and then 4.9 cents in FY 2027. Based on its current share price of 55 cents, this equates to 6.9% and 8.9% dividend yields, respectively.

Pinnacle Investment Management Group Ltd (ASX: PNI)

Another ASX dividend share that Morgans is positive on is Pinnacle Investment Management.

Morgans responded positively to this investment management company’s quarterly update and has retained its buy rating with an improved price target of $24.70.

Commenting on the company, the broker said:

PNI has released its 3Q26 update. The key highlight of the update was 3Q26 flows coming in stronger than expected amid a volatile environment, with PNI’s additional 6.8% investment in Metrics acting as a further vote of confidence in the business. We make mild upgrades to PNI’s FY26F/FY27F/FY28F EPS of ~1%-3%, driven by higher net flow forecasts and the earnings contribution from the increased Metrics stake. Our PT edges up to A$24.70 (from A$23.21) and we maintain our BUY call.

As for income, Morgans is forecasting fully franked dividends of 64 cents per share in FY 2026 and then 81 cents per share in FY 2027.

Based on its current share price of $16.41, this equates to dividend yields of 3.9% and 4.9%, respectively.

The post Morgans says these ASX dividend shares are buys appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• CSL and Wesfarmers among scores of ASX shares hitting fresh 52-week lows
• Pinnacle Investment Management increases Metrics Credit stake in $100.5 million deal
• Here are the top 10 ASX 200 shares today
• Why Accent shares just crashed to a 13-year low

Motley Fool contributor James Mickleboro has positions in Accent Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Pinnacle Investment Management Group. The Motley Fool Australia has positions in and has recommended Pinnacle Investment Management Group. The Motley Fool Australia has recommended Accent Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Three discoveries on the trot have the team at Canaccord Genuity excited about Gorilla Gold Mines Ltd (ASX: GG8), which they say has the potential to more than double in value.

Let’s have a look at the most recent discovery.

Excellent drilling results

Gorilla, in a statement released to the ASX earlier this week, said it had struck a significant intercept at the Sovereign deposit at its Comet Vale gold project in Western Australia.

The drilling intersected 9.3m at 20.6 grams per tonne of gold, in what was “a brand new discovery” at the deposit, the company said.

Gorilla added:

The mineralisation occurs 50m into the footwall of the main lode at Sovereign, a largely untested position, and is visually very different from the mineralisation typically seen at Sovereign. The scale potential of this new high-grade lode is currently under evaluation, noting that individual lodes at Comet Vale are typically continuous over many hundreds of metres both along strike and down-dip.

The company also reported a number of other high-grade results from further drilling at Sovereign.

Gorilla Chief Executive Officer Charles Hughes said regarding the recent discovery:

This is a standout result, one of the best intercepts we’ve delivered at Sovereign, and it’s exciting to get this in a discovery hole in a new high-grade lode position that has seen very little effective drill testing. “Importantly, this mineralisation is geologically distinct from the main Sovereign lodes – in fact, if it wasn’t for the presence of some very coarse gold, it could have been missed! There is no quartz veining and only a tiny amount of sulphides associated with the new lode, which means it would be very easy to overlook. We are now fast-tracking work to define the extent of this lode, including sampling of historical holes that intersected this position and drilling targeted step-outs to specifically target its lateral extents.

Mr Hughes said the company also continued to deliver “excellent” results from its growth drilling at Sovereign.

He added:

With established infrastructure, advanced permitting and proximity to multiple processing options, we are well positioned to rapidly unlock value from these exciting new discoveries at Comet Vale.

Shares looking cheap

The Canaccord team noted that Gorilla’s overall North Kalgoorlie Hub hosted about 1.2 million ounces of gold and remains underexplored.

Canaccord has a speculative buy rating on Gorilla Gold Mines shares and a price target of $1 compared with the current share price of 41 cents.

Gorilla Gold Mines is valued at $278.2 million.

The post This ASX gold explorer could more than double on the back of three recent discoveries: broker appeared first on The Motley Fool Australia.

More reading

• Guess which ASX All Ords gold stock is rocketing 9% today on ‘high-grade’ results

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is in focus today as the company reported Q1 2026 DAYBUE® net sales grew 20% year-on-year, reaching US$101 million. Neuren also saw its Q1 royalty income rise 23% to US$10.4 million, as DAYBUE continued strong momentum.

What did Neuren Pharmaceuticals report?

• Q1 2026 DAYBUE® net sales: US$101 million (up 20% from Q1 2025)
• Q1 2026 royalty income: US$10.4 million (up 23% from Q1 2025)
• Over 250 DAYBUE STIX prescriptions written in Q1 with >80% caregiver satisfaction
• Acadia reaffirmed 2026 DAYBUE net sales guidance: US$460–490 million
• Expected full year 2026 royalty income: US$50–54 million (A$70–77 million)

What else do investors need to know?

Neuren’s partner Acadia recently launched DAYBUE STIX, a new powder version of trofinetide, in the US. Early uptake has been positive, with a high rate of caregiver satisfaction and strong support from healthcare professionals.

A Delphi expert panel now recommends DAYBUE as part of the standard of care for eligible patients with Rett syndrome. Outside the US, clinical trial enrolment in Japan has accelerated, with top-line results now expected between September and November 2026, bringing the timeline forward.

What did Neuren Pharmaceuticals management say?

Neuren CEO Jon Pilcher said:

This was a strong start to the year for DAYBUE. I am very encouraged by the initial uptake and enthusiasm for DAYBUE STIX following the limited launch in Centers of Excellence (COEs) and I look forward to seeing the impact of the recent broader US launch. I see significant potential upside remaining in the US, with penetration rates currently ~60% in the COEs and ~28% in the broader community.

What’s next for Neuren Pharmaceuticals?

Looking ahead, Neuren expects steady growth as DAYBUE roll-out continues in the US, with broader availability for the new STIX powder formulation. The company’s royalty income is forecast to rise in line with guidance, underpinned by increasing adoption and favourable expert recommendations.

Internationally, results from the ongoing trofinetide trial in Japan are now due earlier than previously planned. In Europe, a regulatory review for trofinetide is set to conclude by June 2026. Neuren’s pipeline also includes NNZ-2591, now in Phase 3 trials for Phelan-McDermid syndrome.

Neuren Pharmaceuticals share price snapshot

Over the past 12 months, Neuren Pharmaceuticals shares have risen 1%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.

View Original Announcement

The post Neuren Pharmaceuticals Q1 2026: DAYBUE sales soar appeared first on The Motley Fool Australia.

More reading

• Cleanaway Waste Management hit with landfill levy ruling
• Why Amcor, Credit Corp, Neuren, and Zip shares are charging higher today
• Superloop lifts revenue and customer base
• BWP Group announces successful entitlement offer
• Tabcorp faces AUSTRAC compliance probe

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Shares in Atlantic Lithium Ltd (ASX: A11) have jumped more than 10% after the company said it had agreed to a takeover by a Chinese company.

Share price upside on the table

Atlantic Lithium said in a statement to the ASX that it had entered into a binding scheme of arrangement with Zhejiang Huayou Cobalt Co. to be taken over for a price of 35.4 cents per share.

The company’s shares immediately jumped on the news to be changing hands for 31.5 cents, up 12.5%.

The takeover will be executed in cash and values the company at about $292 million.

The company said its board had considered the offer and found that it “provides Atlantic Lithium shareholders with the most attractive, certain, and accelerated realisation of value on a risk-adjusted basis versus other strategic alternatives”.

Atlantic Lithium’s board is unanimously recommending the deal in the absence of a superior proposal and subject to an independent expert concluding that the scheme is in the best interests of Atlantic Lithium shareholders.

The company said its largest shareholder, Assore International Holdings Limited, which owns 26.4% of the company, had indicated it would vote in favour of the scheme.

Atlantic Lithium Chief Executive Officer Keith Muller said regarding the deal:

The Atlantic Lithium Board has undertaken a detailed evaluation of its strategic options in relation to maximising shareholder value assessed on a risk-adjusted basis and concluded that the Huayou proposal offers an attractive proposition for Atlantic Lithium shareholders, particularly when considered amid ongoing lithium price volatility, complex jurisdictional challenges and against the timing and execution risks attached to financing, developing and operating the Ewoyaa Lithium Project under the Project’s current joint venture arrangements. Huayou’s proposal acknowledges Ewoyaa as a highly attractive hard rock lithium asset capable of serving the growing global electric vehicle and energy storage markets. We welcome the endorsement of the Company’s major shareholder, Assore, towards the Transaction, which is intended to facilitate a clearer direction for the Project towards the achievement of first production of lithium. In doing so, the Transaction is expected to accelerate the delivery of the substantial benefits anticipated for Ghana through the construction and operation of the Project, including, notably, the socio-economic development of the Project’s host communities.

The Ewoyaa project, once developed, would be Ghana’s first lithium mine.

Second approach

Atlantic Lithium said in its most recent quarterly report that it had ceased discussions with “an undisclosed entity in respect of a potential corporate transaction, following the receipt of a conditional, non-binding, indicative change of control proposal for the acquisition of 100% of the Company’s share capital by way of a scheme of arrangement”.

The post Why is this ASX lithium share surging higher today? appeared first on The Motley Fool Australia.

More reading

• ASX lithium stocks to buy amid commodity price rocketing 58% already this year
• Why this ASX 200 rocket stock is crashing again today
• Morgans says these ASX dividend shares are buys
• This ASX gold explorer could more than double on the back of three recent discoveries: broker
• Neuren Pharmaceuticals Q1 2026: DAYBUE sales soar